Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
417 studies found for:    Amyloidosis
Show Display Options
Rank Status Study
21 Active, not recruiting Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Bortezomib (Velcade) and Dexamethasone
22 Recruiting Institutional Registry of Amyloidosis
Condition: Amyloidosis
23 Unknown  Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
Condition: Amyloidosis
Intervention: Drug: Lenalidomide, Dexamethasone and Cyclophosphamide
24 Completed Allo SCT in Amyloidosis Non-interventional Study
Condition: AL Amyloidosis
25 Not yet recruiting A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: Carfilzomib;   Drug: Thalidomide;   Drug: Dexamethasone
26 Unknown  Study of Systemic Amyloidosis Presentation and Prognosis
Condition: Amyloidosis
27 Completed Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis
Condition: Amyloidosis
Intervention: Drug: melphalan, thalidomide and dexamethasone
28 Active, not recruiting Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: Bendamustine;   Drug: Dexamethasone
29 Withdrawn Mixed Chimeric Transplantation for Primary Amyloidosis
Condition: Amyloidosis
Intervention: Procedure: autologous followed by nonmyeloablative allogeneic transplant
30 Completed Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation
Condition: Amyloidosis
31 Recruiting Carpal Tunnel/Amyloidosis Blood Sample Study
Conditions: Carpal Tunnel Syndrome;   Amyloidosis
Intervention: Procedure: Blood Draw
32 Enrolling by invitation Recurrent AA Amyloidosis After Renal Transplantation
Condition: AA Amyloidosis
33 Recruiting Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
34 Active, not recruiting Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Condition: Primary Amyloidosis
Intervention: Drug: NEOD001
35 Completed
Has Results
Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
Condition: Familial Amyloid Polyneuropathy
Interventions: Drug: Fx-1006A;   Drug: Placebo
36 Recruiting The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: NEOD001;   Drug: Placebo
37 Completed Radioimmunoimaging of AL Amyloidosis
Condition: AL Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
38 Completed Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: cyclophosphamide;   Drug: lenalidomide;   Drug: dexamethasone
39 Recruiting Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography
Condition: Cardiac Amyloidosis
Intervention: Drug: F-18 florbetapir PET
40 Recruiting Oral Doxycycline Administered as an Adjunct to Plasma Cell Directed Therapy in Light Chain Amyloidosis
Condition: Primary Systemic Amyloidosis
Intervention: Drug: Doxycycline

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years